It is important to note the limited sample size in this cohort and the inclusion of three patients with uveal melanoma in the 900 mg cohort; however, a similar trend was observed for patients with anti–PD-1 relapsed or refractory disease in part 2A, wherein the ORR of the cobolimab 300 mg cohort was greater (6.9%) than that of the cobolimab 100 mg cohort (0%). Here, PDCD1 is linked to uveal melanoma.